Relief Effort Progress Highlighted at the Clinton Global Initiative Annual Meeting in New York, September 26-29, 2015
IRVINE, Calif - Monday, September 28th 2015 [ME NewsWire]
(BUSINESS WIRE)-- Masimo (NASDAQ: MASI) announced progress today at the 2015 Clinton Global Initiative Annual Meeting towards its commitment to donate $5 million in Signal Extraction Technology® Pulse Oximeters and Pulse CO-Oximeters® and other medical equipment to Jordanian hospitals to help improve patient care for Syrian and Iraqi refugees, as well as Jordanian citizens. A progress report video highlighting the Masimo relief effort was featured at the Plenary Session called Investing in Prevention and Resilient Health Systems. The first shipment of equipment is already in use at Al-Bashir hospital in Amman. The rest of the equipment will arrive at the Ministry of Health Office in Jordan shortly. Masimo also committed to provide ongoing training and technical support to the clinicians in Jordan.
The wars in Syria and Iraq are one of the largest ongoing humanitarian crises in the world, with over an estimated million people seeking refuge now living within Jordan’s borders, more than 600,000 of whom are registered with the United Nations High Commissioner for Refugees (UNHCR). Managing healthcare is a critical requirement of stability during crises and, while new hospitals are being built near refugee camps, the vast majority of refugees reside in existing communities, heightening the demand for health services throughout Jordan. The significant burden of providing healthcare services both for routine and emergency needs is worsening daily.
“The people of Jordan have opened their hearts and country to help their neighbors in need,” said Joe Kiani, Founder and CEO of Masimo. “The situation in Syria keeps getting worse. The people of Jordan are our heroes – taking in the Palestinian refugees, the Iraqi refugees, then the Egyptian refugees, and now the large influx of Syrian refugees. We knew our plan for aid needed to be long-term. We not only donated the much needed oximeters, other medical equipment, and supplies but we also committed to train and provide continued technical support for the Jordanian clinicians that assist in the front line care of the people of Jordan. The need is great and it is too overwhelming for just a few countries to shoulder. As global citizens, we all need to get involved and help the people of Syria and those trying to save them.”
Masimo’s commitment to Jordan is one of several ongoing CGI commitments, and was made at a roundtable meeting convened by CGI in 2014, at which President Clinton and his Majesty King Abdullah Il ibn Al Hussein of Jordan met with Masimo’s Joe Kiani, among others, to discuss the humanitarian crisis.
The measurements provided by pulse oximeters are often referred to as the “fifth vital sign.” In a report published by the Jordanian government, they are identified as one of the most needed pieces of hospital equipment. Pulse oximeters allow a health worker to monitor a person’s oxygen levels. Confirming oxygen levels in the blood is critical as it helps identify those in need of care, those who are deteriorating, and those who are not. Pulse oximeters are widely used from health clinics to emergency departments, from surgery and the intensive care unit to the general floor. Over 100 million patients are monitored with Masimo SET® pulse oximeters around the world and in more than 100 comparative studies Masimo SET® outperformed other technologies. Researchers have found that Masimo SET® in combination with changes in clinical practice led to a reduction in retinopathy of prematurity (ROP) in preterm babies in the neonatal intensive care unit (NICU)¹ and an increase of 31% in the detection of newborns with critical congenital heart disease (CCHD) when used as a part of the CCHD screening protocol.2 Researchers found improved outcomes3 following the installation of continuous patient monitoring with Masimo SET® on post-surgical patients, including that zero patients suffered brain damage or died over a five-year period.4 A recent study with a Masimo Pulse CO-Oximeter® (SpHb and PVI) also showed that 30-day mortality after surgeries dropped by 25%.5
1. Castillo A, Deulofeut R, Critz A, Sola A. Prevention of retinopathy of prematurity in preterm infants through changes in clinical practice and SpO2 technology. Acta Paediatr. 2011 Feb;100(2):188-92.
2. de-Wahl Granelli A, Wennergren M, Sandberg K, Mellander M, Bejlum C, Inganäs L, Eriksson M, Segerdahl N, Agren A, Ekman-Joelsson BM, Sunnegårdh J, Verdicchio M, Ostman-Smith I. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009 Jan 8;338:a3037.
3. Taenzer AH, Pyke JB, McGrath SP, Blike GT. Impact of pulse oximetry surveillance on rescue events and intensive care unit transfers: a before-and-after concurrence study. Anesthesiology. 2010 Feb;112(2):282-7.
4. Taenzer et al. The Dartmouth Experience. APSF Newsletter. Spring-Summer 2012. Volume 27, No. 1, 1-28.
5. Ponsonnard S, Yonnet S, Marin B, Cros J, Ben Miled S, Nathan N. “Continuous Hb and plethysmography variability index (PVI) monitoring is associated to a decreased mortality at the scale of a whole hospital.” Proceedings of the European Society of Anaesthesiology’s Euroanaesthesia 2015 Annual Congress, May 30-June 2, Berlin, Germany, 16AP3-2, Room A1 – Poster Abstract Presentation Session, e-Board 8.
Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies. Our mission is to improve patient outcomes and reduce the cost of care by taking noninvasive monitoring to new sites and applications. In 1995, the company debuted Masimo SET® Measure-through-Motion and Low Perfusion™ pulse oximetry, which has been shown in multiple studies to significantly reduce false alarms and accurately monitor for true alarms. The benefits of Masimo SET® have been proven in more than 100 independent and objective studies and it is estimated to be used on more than 100 million patients in leading hospitals and other healthcare settings around the world. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI). Additional information about Masimo and its products may be found at www.masimo.com.
About the Clinton Global Initiative
Established in 2005 by President Bill Clinton, the Clinton Global Initiative (CGI), an initiative of the Clinton Foundation, convenes global leaders to create and implement solutions to the world's most pressing challenges. CGI Annual Meetings have brought together 190 sitting and former heads of state, more than 20 Nobel Prize laureates, and hundreds of leading CEOs, heads of foundations and NGOs, major philanthropists, and members of the media. To date, members of the CGI community have made more than 3,200 Commitments to Action, which have improved the lives of over 430 million people in more than 180 countries.
In addition to the Annual Meeting, CGI convenes CGI America, a meeting focused on collaborative solutions to economic recovery in the United States; and CGI University (CGI U), which brings together undergraduate and graduate students to address pressing challenges in their community or around the world. This year, CGI also convened CGI Middle East & Africa, which brought together leaders across sectors to take action on pressing social, economic, and environmental challenges.
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including: total hemoglobin (SpHb®) contributes to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions with comparable accuracy and unique advantages, including: immediate and continuous results that enable earlier treatment without causing invasive trauma in all patients and in every clinical situation; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI are trademarks or registered trademarks of Masimo Corporation.
Irene Paigah, 858-616-8689